SNT 8.33% 2.2¢ syntara limited

Ann: Presentation - quarterly investor update, page-2

  1. 5,624 Posts.
    lightbulb Created with Sketch. 665
    'US FDA clears IND filed by the University of Rochester (NY) for a phase 1c/2a clinical trial of PXS‐5505 in hepatocellular
    carcinoma (HCC) patients. PXS‐5505 to be added to current chemotherapy standard of care as first line therapy in newly
    diagnosed patients with unresectable HCC carcinoma'


    'unresectable' add that to my vocab

    https://hotcopper.com.au/data/attachments/4038/4038545-289b85ce87bbd9828d3245939f36c085.jpg

    Hold on tight!
    Its going to be one interesting year...most impressive prospective Biotech by far
    Commercially minded Gary! Shareholders are fortunate to have him!
    Practical achievable commercial targets! Well done!
    Speed and reach of network...incredible!
    Impressive pipeline
    Drug discovery team....WORLD CLASS!
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
2.2¢
Change
-0.002(8.33%)
Mkt cap ! $26.26M
Open High Low Value Volume
2.2¢ 2.2¢ 2.2¢ $4 197

Buyers (Bids)

No. Vol. Price($)
5 383913 2.2¢
 

Sellers (Offers)

Price($) Vol. No.
2.4¢ 29356 1
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.